[go: up one dir, main page]

CY1111369T1 - Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη - Google Patents

Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη

Info

Publication number
CY1111369T1
CY1111369T1 CY20111100353T CY111100353T CY1111369T1 CY 1111369 T1 CY1111369 T1 CY 1111369T1 CY 20111100353 T CY20111100353 T CY 20111100353T CY 111100353 T CY111100353 T CY 111100353T CY 1111369 T1 CY1111369 T1 CY 1111369T1
Authority
CY
Cyprus
Prior art keywords
phenol
propyl
ethyl
methyl
paraketamol
Prior art date
Application number
CY20111100353T
Other languages
English (en)
Inventor
Petra Bloms-Funke
Klaus Schiene
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37025148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111369(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of CY1111369T1 publication Critical patent/CY1111369T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά μια σύνθεση που περιέχει ως συστατικά (α) την ένωση 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινόλη και (β) Παρακεταμόλη ή ένα παράγωγο αυτής, ένα φαρμακευτικό σκεύασμα και μια μορφή δόσης που περιέχει την αναφερθείσα σύνθεση, καθώς και μια μέθοδο για την αντιμετώπιση του πόνου, π.χ. του χρόνιου ή οξέος πόνου, η οποία χαρακτηρίζεται από το ότι τα συστατικά (α) και (β) χορηγούνται ταυτόχρονα ή διαδοχικά σε ένα θηλαστικό, όπου το συστατικό (α) μπορεί να χορηγηθεί πριν ή μετά το συστατικό (β) και όπου τα συστατικά (α) ή (β) χορηγούνται στο θηλαστικό είτε μέσω της ίδιας είτε μέσω διαφορετικής οδού χορήγησης.
CY20111100353T 2006-04-28 2011-04-05 Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη CY1111369T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06008851 2006-04-28
EP07724562A EP2012764B1 (en) 2006-04-28 2007-04-25 Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol

Publications (1)

Publication Number Publication Date
CY1111369T1 true CY1111369T1 (el) 2015-08-05

Family

ID=37025148

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100353T CY1111369T1 (el) 2006-04-28 2011-04-05 Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη

Country Status (24)

Country Link
EP (1) EP2012764B1 (el)
JP (2) JP5496653B2 (el)
KR (1) KR101396166B1 (el)
CN (1) CN101431990B (el)
AT (1) ATE494889T1 (el)
AU (1) AU2007247481B2 (el)
BR (1) BRPI0710682B8 (el)
CA (1) CA2650423C (el)
CY (1) CY1111369T1 (el)
DE (1) DE602007011913D1 (el)
DK (1) DK2012764T3 (el)
EC (2) ECSP088793A (el)
ES (1) ES2356093T3 (el)
HR (1) HRP20110076T1 (el)
IL (1) IL194883A (el)
MX (1) MX2008013779A (el)
NO (2) NO341602B1 (el)
NZ (1) NZ571442A (el)
PL (1) PL2012764T3 (el)
PT (1) PT2012764E (el)
RU (1) RU2442576C2 (el)
SI (1) SI2012764T1 (el)
WO (1) WO2007128413A1 (el)
ZA (1) ZA200810124B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
KR101607112B1 (ko) * 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
DK2680833T3 (en) * 2011-03-04 2016-05-23 Gruenenthal Gmbh PARENTERAL SUBMISSION OF TAPENTADOL
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
NO2680834T3 (el) 2011-05-03 2018-03-17
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
ES2710299T3 (es) 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
ES3027562T3 (en) 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PE20030527A1 (es) * 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
EP1562567B1 (de) * 2002-11-22 2017-06-14 Grünenthal GmbH Kombination ausgewählter analgetika mit cox ii-inhibitoren

Also Published As

Publication number Publication date
WO2007128413A1 (en) 2007-11-15
DK2012764T3 (da) 2011-02-28
EP2012764A1 (en) 2009-01-14
BRPI0710682A2 (pt) 2011-08-23
NO341602B1 (no) 2017-12-11
ATE494889T1 (de) 2011-01-15
PL2012764T3 (pl) 2011-04-29
RU2008146816A (ru) 2010-06-10
CA2650423A1 (en) 2007-11-15
HK1127289A1 (en) 2009-09-25
DE602007011913D1 (de) 2011-02-24
CA2650423C (en) 2014-08-12
BRPI0710682B8 (pt) 2021-05-25
HRP20110076T1 (hr) 2011-02-28
AU2007247481B2 (en) 2013-02-14
JP2009535313A (ja) 2009-10-01
ZA200810124B (en) 2009-08-26
NZ571442A (en) 2011-09-30
NO343505B1 (no) 2019-03-25
ES2356093T3 (es) 2011-04-04
ECSP17000643A (es) 2018-06-30
RU2442576C2 (ru) 2012-02-20
JP2013213045A (ja) 2013-10-17
KR101396166B1 (ko) 2014-05-27
CN101431990A (zh) 2009-05-13
IL194883A0 (en) 2009-08-03
IL194883A (en) 2012-10-31
NO20084542L (no) 2008-10-28
MX2008013779A (es) 2008-11-14
BRPI0710682B1 (pt) 2020-09-24
JP5496653B2 (ja) 2014-05-21
PT2012764E (pt) 2011-02-02
ECSP088793A (es) 2008-11-27
KR20090006219A (ko) 2009-01-14
AU2007247481A1 (en) 2007-11-15
EP2012764B1 (en) 2011-01-12
CN101431990B (zh) 2011-08-03
NO20171831A1 (no) 2008-10-28
SI2012764T1 (sl) 2011-03-31

Similar Documents

Publication Publication Date Title
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
ZA200810125B (en) Pharmaceutical combination comprising 3- (3-dimethy-lamin0-1-ethyl-2-methyl-pr0pyl)-phenol and an NSAID
WO2010025931A3 (en) Pharmaceutical combination of 3- (3-dimethylamino-1-ethyl-2 -methyl-propyl) - phenol and an antiepileptic
AU2016219643A1 (en) Pharmaceutical combination for the treatment of pain
GT200700034A (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti-cd40
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
CY1118661T1 (el) Φαρμακευτικη συνθεση, φαρμακευτικη δοσολογικη μορφη, διαδικασια για την παρασκευη τους, μεθοδοι για αντιμετωπιση και χρησεις αυτων
WO2007143607A3 (en) Method of treating atrophic vaginitis
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
BRPI0622054B8 (pt) composto e composição farmacêutica
WO2007125501A3 (en) Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0922789A2 (pt) peptídeo de ligação de albumina intermediador para reconhecimento de doença
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
MX2009011900A (es) Curacion de herida diabetica.
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica
BRPI0506551A (pt) uso do metronidazol para a preparação de uma composição farmacêutica